It is especially interesting to note that treatment failure has been shown with baclofen in MS patients (Stroet et al., 2013), and the inability of baclofen to target TLR4-induced pro-inflammatory cytokine production might contribute to these effects. The gene discussed is TLR4; the disease is myeloid sarcoma.